Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

NCT05743881 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05743881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05743881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 15, 2023
Completion date
August 31, 2029
Enrollment
186 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

human metapneumovirus, respiratory syncytial virus